Chapter 12 Current management of hormone-refractory prostate cancer

Advances in Oncobiology

Volumn 3, Issue C, 1999, Pages 235-255

  Sartor, Oliver ^a   Figg, William D ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957042210     PISSN: 1569254X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-254X(99)80013-2     Document Type: Review

References (75)

1. Akimoto S., Inomiya H., Akakura K., Shimazaki J., and Ito H. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: Univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Jpn. J. Clin. Oncol. 27 (1997) 258-262
2. Amato R.J., Logothetis C.J., Dexeus F.H., et al. Preliminary results of a phase II trial of estramustine and vinblastine for patients with progressive hormone refractory prostate cancer. Proc. Am. Assoc. Cancer Res. 32 (1991) 111A
3. Bissada N.K., and Kaczmarek A.T. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J. Urol. 153 (1995) 1944-1945
4. Bloomfield D.J., Krahn M.D., and Tannock I.F. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomized trial with palliative endpoints. Proc. Am. Soc. Clin. Oncol. 16 (1997) 317A
5. Broder S., Yarchoan R., Collins J.M., et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS related complex: Clinical pharmacology and suppression of virus replication in vitro. Lancet 2 (1985) 627-630
6. Citrin D.L., Kies M.S., Wallemark C.B., et al. A phase II study of high-dose estrogens (diethylbestrol diphosphate) in prostate cancer. Cancer 56 (1985) 457-560
7. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321 (1989) 419-424
8. Culig Z., Hobisch A., Cronauer M.V., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 12 (1993) 1541-1550
9. Culig Z., Hobisch A., Hittmair A., et al. Androgen receptor gene mutations in prostate cancer: Implications for disease progression and therapy. Drugs Aging 10 (1997) 50-58
10. Dawson N.A. Eligibility and response criteria in hormone refractory prostate cancer: A need for consensus. Proc. Am. Soc. Clin. Oncol. 16 (1997) 317A
11. Dawson N.A., Cooper M.R., Figg W.D., et al. Activity of suramin in hormone-refractory sprostate cancer when hydrocortisone treatment and flutamide withdrawal are removed as potentially confounding variables. Cancer 76 (1995) 453-462
12. Dawson N., Figg W.D., Brawley O.W., et al. A phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: Simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin. Cancer Res. 4 (1998) 37-44
13. Dawson N.A., and McLeod D.G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome. J. Urol. 153 (1995) 1946-1947
14. (Abstract 298). Dixon S.C., Horti K., Logothetis C., et al. TNP-470 upregulates the expression of prostate specific antigen. Proc. Am. Assoc. Cancer Res. 39 (1998)
15. Dupont A., Gomez J.-L., Cusan L., et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150 (1993) 908-913
16. Eisenberger M.A., Rainy L.M., Jodrell D.I., et al. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J. Natl. Cancer Inst. 85 (1993) 611-621
17. Eisenberger M.A., Sinibaldi V.J., Renyo L.M., et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol. 13 (1995) 2174-2186
18. Ferro M.A., Gillatt D., Symes M.O., and Smith P.J.B. High dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response. Urology 34 (1989) 134-138
19. Figg W.D., Ammerman K., Patronas N., et al. Lack of correlation between prostate specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. 14 (1996) 513-517
20. Figg W.D., Dawson N., Middleman M.N., et al. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with "hormone-refractory" prostate cancer. Acta Oncol. 35 (1996) 763-765
21. Fong C.J., Sutkowski D.M., Braun E.J., et al. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol. 149 (1993) 1190-1194
22. Fossa S.D., Dearnaley D.P., Law M., et al. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann. Oncol. 3 (1992) 361-366
23. Fowler Jr. J.E. Endocrine therapy for localized prostate cancer. In: Rous S.N. (Ed). Urology Annual Vol. 10 (1996), Blackwell Science, Austin, TX 57-77
24. Hansen R., Moynihan T., Beatty P., et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 37 (1983) 358-361
25. Herrada J., Hossan B., Amato R., et al. Adrenal androgens predict for early progression to flutamide withdrawal in patients with androgen independent prostate carcinoma. Proc. Am. Soc. Clin. Oncol. 13 (1994) 734A
26. Huan S.D., Gerridzen R.G., Yau J.C., and Stewart D.J. Antiandrogen withdrawal syndrome with nilutamide. Urology 49 (1997) 632-634
27. Hudes G.H., Greenberg R., Krigel R., et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J. Clin. Oncol. 10 (1992) 154-1761
28. Hudes G.R., Nathan F., Khater C., et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 15 (1997) 3156-3163
29. Hudes G., Roth B., Loehrer P., et al. Phase III trial of vinblastine vs. vinblastine + estramustine phosphate for metastatic hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 16 (1997) 316A
30. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1 (1941) 293-297
31. Hussain M.H., Pienta K.J., Redman B.G., et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74 (1994) 100-103
32. Jazieh A.R., Munshi N.C., Muirhead M., and Ross S.W. Clinical efficacy of diethylstilbestrol treatment in post-orchiectomy progressive prostate cancer. Proc. Am. Assoc. Cancer Res. 35 (1994) 1394A
33. Joyce R., Fenton M.A., Rode P., et al. High dose bicalutamdie for androgen independent prostate cancer: Effect of prior hormonal therapy. J. Urol. 159 (1998) 149-153
34. Abstract. Kantoff P.W., Conaway M., Winer E., et al. Hydrocortisone with and without mitoxantrone in patients with hormone refractory prostate cancer: Preliminary results from a prospective randomized cancer and leukemia group B study comparing chemotherapy to best supportive care. Proc. Am. Soc. Clin. Oncol. 15 (1996)
35. Kelly W.K., Curley T., Leibertz C., et al. Prospective evaluation of hydrocortisone and suramin in hormonally relapsed prostate cancer. J. Clin. Oncol. 13 (1995) 2208-2213
36. Kelly W.K., Scher H.I., Mazumdar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11 (1993) 607-615
37. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer Statistics, 1998. CA Cancer J. Clin. 48 (1998) 6-29
38. Lewington V.J., McEwan A.J., Ackery D.M., et al. A prospective randomized double-blind cross-over study to examine the efficacy of strontium-89 in bone palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer 27 (1991) 954-958
39. Lokiich J. A phase I study of continuous infusion 5-fluorouracil in advanced hormone-refractory prostate cancer: An Illinois cancer center study. Cancer 73 (1992) 1536
40. Morote J., Lorente J.A., Vallejo C., et al. Prostate specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate. Actas Urol. Esp. 18 (1994) 656-659
41. Myers C., Cooper M., Stein C., et al. Suramin. A novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J. Clin. Oncol. 10 (1992) 881-889
42. (for the European Organization for Research and Treatment of Cancer-Genitourinary Group). Newling D.W.W., Denis L., and Vermeylen K. Orchiectomy versus Goserelin and Flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 72 (1993) 3793-3798
43. Osborn J.L., Smith D.C., and Trump D.L. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am. J. Clin. Oncol. 20 (1997) 308-310
44. Petrylak, D.P., Shelton, G., Judge, T. et al. Phase I trial of docetaxel and estamustine in androgen-insensitive prostate cancer. Proc. Am. Soc. Clin. Oncol. 16, 310A.
45. Pienta K.J., Redman B., Hussain M., et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 12 (1994) 2005-2012
46. Porter A.T., McEwan A.J.B., Powe J.E., et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 25 (1993) 805-810
47. Resche I., Chatal J.F., Pecking A., et al. A dose controlled study of samarium-153 EDTMP in treatment of patients with painful bone metastases. Eur. J. Cancer 33 (1997) 1583-1591
48. Rhagavan D., Cox K., Pearson B.S., et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br. J. Urol. 72 (1994) 625-628
49. Robertson C.N., Roberson K.M., Padilla G.M., et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst. 88 (1996) 908-917
50. Rosen P.J., Mendoza E.F., Landaw E.M., et al. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy. J. Clin. Oncol. 14 5 (1996) 1626-1636
51. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia and prostatic adenocarcinoma between the ages of 20-69: An autopsy study. In Vivo 8 (1994) 439-443
52. Sartor O. Prostate-specific antigen changes before and after administration of an angiogenesis inhibitor. Oncol. Reports 2 (1995) 1101-1102
53. Sartor O., Cooper M., Weinberger M., et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer Inst. 86 (1994) 222-227
54. Sartor O., Dawson N., Figg W.D., et al. Activity of flutamide withdrawal in "hormone-refractory" prostate cancer before, concomitantly, and after adrenocortical suppression. Proc. Am. Soc. Clin. Oncol. 14 (1995) 629A
55. 153-samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate Cancer. 92nd Ann. Meet. Amer. Urol. Assoc. 157 (1997) 1252A
56. Sartor O., and Weinberger M. Surprising activity of flutamide in "hormone-refractory" patients with stage TxNxM0 prostate cancer. Proc. Am. Soc. Clin. Oncol. 15 (1996) 267A
57. Sartor O., Weinberger M., Moore A., et al. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52 (1998) 252-256
58. Schellhammer P.F., Venner P., Haas G.P., et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol. 157 (1997) 1731-1735
59. Scher H.I., and Kelly W.K. The flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11 (1993) 1566-1572
60. Scher H.I., Steineck G., and Kelly W.K. Hormone-refractory (D3) prostate cancer: Refining the concept. Urology 46 2 (1995) 142-148
61. Seidman A.D., Scher H.I., Petrylak D., et al. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point in hormone refractory prostate cancer. J. Urol. 147 (1992) 931-934
62. Sella, A., Kilbourn, r., Amato, R. et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 12, 683-688.
63. Small E.J., Baron A., and Apodaca D. Simultaneous anti-androgen withdrawal and treatment with ketoconazole/hydrocortisone in patients with advanced "hormone-refractory" prostate cancer. Proc. Am. Soc. Clin. Oncol. 16 (1997) 313A
64. Small E.J., Baron A.D., Fippin L., and Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157 (1997) 1204-1207
65. Small E.J., and Carroll P.R. Prostate specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 43 (1994) 408-410
66. Small E.J., and Srinivas S. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76 (1995) 1428-1434
67. Sridhara R., Eisenberger M.A., Sinibaldi V.J., et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol. 13 (1995) 2944-2953
68. Storlie J.A., Buckner J.C., Wiseman G.A., et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate cancer. Cancer 76 (1995) 96-100
69. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7 (1989) 590-597
70. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J. Clin. Oncol. 14 (1996) 1756-1764
71. Taplin M.E., Bubley G.J., Shuster T.D., et al. Androgen receptor mutations in metastatic androgen independent prostate cancer. N. Engl. J. Med. 332 (1995) 1393-1398
72. Thalmann G.N., Sikes R.A., Chang S., et al. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCAP model of human prostate cancer. J. Natl. Cancer Inst. 88 (1996) 794-802
73. Veldscholte J., Ris-Stalpers C., Kuipper G.G.J.M., et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Commun. 173 (1990) 534-540
74. Walzer Y., Oswalt J., and Soloway M.S. Estramustine phosphate-hormone, chemotherapeutic agent, or both?. Urology 24 1 (1984) 53-58
75. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 71 (1993) 1098-1109